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years: (T1-3 N2) 73 (59-87)% vs (T4 N0/1) 90 (82-98)% vs (T1-3 
N3/T4 N2) 83 (69-97), p=0.03). In multivariate proportional 
hazard regression analysis including the factors gender, PCI 
(yes/no), histology (scc/adeno), TN-subgroups, only gender 
remained significant (hazard ratio female vs male: 2.44 
[1;5.98], p=0.05). 5-Year survival from the diagnosis of 
isolated brain relapse onwards was 22% in contrast to 3% for 
patients after diagnosis of relapses at any site (p=0.08). 
Conclusions: A similar incidence of isolated brain relapses 
was found after trimodality or definitive RT/CT. The 
incidence of PCI was low in both arms without difference. 
Pts. with isolated brain relapse have a good prognosis after 
salvage therapy. Given this and the moderate incidence of 
brain metastases, PCI does not seem to provide a major 
therapeutic advantage.  
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Purpose/Objective: Biologically adaptive radiotherapy 
depends on early detection of response of tumor and/or 
normal tissue to allow timely adaptation of the remaining 
fractions. There is, however, little data on feasible time-
points to measure response of tumor and normal tissues with 
FDG PET. We are therefore currently performing a study with 
weekly FDG PET/CT in non-small cell lung cancer patients 
during therapy. The aim of this paper is to detect early 
response of normal tissues. 
Materials and Methods: All patients received 24 x 2.75 Gy 
concurrent with daily low dose cisplatinum. FDG PET/CT 
scans were made in treatment position directly before 
fractions 1, 6, 11, 16, and 21 and 1-3 months post-treatment. 
A region of interest (ROI) was defined as the part of the 
esophagus planned to receive more than 40 Gy physical dose, 
excluding the GTV and lymph nodes with a 5 mm margin. A 
lung ROI was defined as the region of lung tissue planned to 
receive more than 40 Gy excluding the primary GTV with a 5 
mm margin. Appropriate margins were used such that, after 
rigid registration based on the bony anatomy, the ROIs did 
not intersect tumor, heart or chest wall in any of the follow 
up scans. For the esophagus and lung ROIs, cumulative FDG 
uptake histograms were made for each weekly scan. For the 
long ROI, also the mean CT number was evaluated in each 
weekly scan. 
Results: In 7 out of 9 patients, a significantly increased SUV 
in the esophagus (SUV>4) could be seen before fractions 16 
and/or 21. The increased uptake occurred in regions of the 
esophagus planned to receive more than 63 Gy. However, the 
delivered dose at which esophagitis was first detected on PET 
ranged from 34 to 54 Gy over the 7 patients. Clinical 
complaints generally preceded PET findings. The patients 
without PET esophagitis had a planned esophagus dose of 
<50Gy. Interestingly, none of the patients showed increased 
FDG uptake in the lung ROI during treatment (SUV change 
from -0.18 to 0.17, all non-significant). Lung ROI CT number 
changes during treatment were small and often negative (-93 
to 29 HU, all non-significant). 
In the 5 available follow-up scans, only two taken 3 months 
after treatment showed changes in the lung ROI: the mean 
SUV increased 1.4-2, and the mean density 140-260 HU. In all 
follow-up scans the FDG uptake in the esophagus had 
subsided. 
Conclusions: This study shows that FDG uptake in the 
esophagus increases during chemoradiation at varying 
delivered doses and can be used to gauge early radiation 
damage. There was, however, no evidence of early PET or CT 
changes in the healthy lung receiving >40 Gy. The lack of CT 
response in this study (based on diagnostic CT) contradicts 
findings in the literature based on CBCT. The lack of early 
FDG uptake in the lung region receiving a high dose indicates 
that lung inflammation will not interfere with tumor response 
measurements.  
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Purpose/Objective: To investigate the correlation of lung 
dose volume parameters with radiation pneumonitis (RP) in 
non-small-cell lung cancer (NSCLC) and pulmonary 
metastases treated with stereotactic body radiotherapy 
(SBRT). 
Materials and Methods: From January 2006 to January 2014, 
72 patients with primary or metastatic lung tumors 
underwent SBRT with total dose of 40 Gy (47.22%) and 50 Gy 
(52.78%) in 5 fractions with Linac or Tomotherapy. The dose 
was prescribed to the isocenter, the fractionation schedule 
has been chosen according to diameter and location of the 
lesion (central vs peripheral). 54/72 (75%) patients had 
primary lung cancer and 18/72 (25%) patients had solitary 
secondary lung lesion. Dosimetric factors were extracted 
from the dose-volume histogram (DVH). PTV consisted of GTV 
plus 1 cm in cranial-caudal direction and 0.5 cm in others 
directions; after installation of Tomotherapy, expansion was 
0.5 cm in all directions. Median tumor diameter was 20 mm 
(range 10-60) and 11 mm (5-22), median GTV was 5.87 cc 
(0.88-27.90) and 3.34 cc (0.33-9.07), median PTV was 28.48 
cc (2.7-133.8) and 14.785 cc (7.3-113.3) for primary and 
secondary lung cancer, respectively. Response was evaluated 
with CT and/or FDG-PET imaging 3-4 months after the end of 
SBRT and every 4-6 months thereafter. Toxicity was 
evaluated according to CTCAE v3.0. We retrospectively 
analyzed clinical, treatment-related and dosimetric factors. 
Factors including total radiation dose, site of lesion, 
diameter, GTV, PTV, V5, V10, V20, V30 and mean lung dose 
(MLD) of ipsilateral lung were considered in order to evaluate 
the development of RP using the Cox proportional hazards 
model. The predictive accuracy for RP was assessed by using 
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receiver operating characteristic curve (ROC) analysis to 
define the cut-off points for significant parameters.  
Results: Median follow-up time was 20.5 months (range 4 – 
91) and 18 months (14-80) for primary and secondary lung 
cancer. RP G1-2 has been observed in 23/54 patients 
(42.59%); no pulmonary toxicity >G2 has occurred, as there 
has been no toxicity of controlateral lung and other organs at 
risk. Univariate statistical analysis showed that 
GTV(p=0.036), PTV (p=0.022), MLD (p=0.003) and V5 
(p=0.002), V10 (p=0.002), V20 (p=0.012), V30 (p=0.002) were 
significant variables for the risk of developing RP. 
Multivariate statistical analysis has found that the predictor 
variables of RP are V5 (p=0.004), V10 (p=0.009), V20 
(p=0.014), V30 (p=0.007) and the MLD (p=0.011). The 
greatest risk was connected to the variable V30 (HR 1.985 ).  
On the ROC curve, the cut-off values of ipsilateral lung 
V5,V10,V20,V30 and MLD were 29.50%,19.50%,9.55%,4.58% 
and 4.7%, respectively (Fig.1). A cutoff of 4.58% for V30 had 
a sensitivity of 80% and specificity of 82.1%. 
 
Conclusions: In our study stereotactic body radiotherapy was 
well tolerated for primary and secondary lung cancer 
treatment. V5, V10, V20, V30 and MLD were significantly 
predictive of RP.  
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Purpose/Objective: Analyse clinical and dosimetric results of 
helical tomotherapy (HT) and rapidarc (RA) in complex 
adjuvant breast and nodes (IMC and supraclavicular nodes) 
irradiation with simultaneous-integrated boost. 
Materials and Methods: Seventy-nine patients were included 
in the study (37 HT and 42 RA). Treatments were in 29 
fractions. Dose prescriptions were 63.8 Gy (HT) and 63.2 Gy 
(RA) in the tumour bed, 52.2 Gy in the breast (HT and RA), 
50.4 Gy in supraclavicular nodes and IMC with HT and 52.2 Gy 
and 49.3 Gy in IMC and supraclavicular nodes with RA. 
Margins to the PTV were larger in the rapidarc group (7mm vs 
5mm). 
Results: For HT cohort, the coverage of clinical target 
volumes (CTV) was as follows: CTV tumour bed: 99,4%±2,4; 
CTV breast: 98,4%±4,3; CTV supraclavicular nodes: 
99,5%±1.2; CTV IMC: 96,5%±13,9. For RA cohort, the coverage 
of CTV was as follows: CTV tumour bed: 99,7%%±0,5, CTV 
breast: 99,3 %±0,7; CTV supraclavicular nodes: 99,6%±1,4; 
CTV IMC: 99,3%±3. For ipsilateral lung, Dmean and V20 were 
13, 5 Gy±1, 4, 20,9%±4,9 (HT) and 13,6 Gy±1,4, 20,1%±3,2 
(RA). Dmean and V30 of the heart were 7,4 Gy±1,4, 1%±1 
(HT) and 10,3 Gy±4,2, 2,5%±3,9 (RA). For controlateral breast 
Dmean was 3, 6 Gy±0,7 (HT) and 4,6 Gy±0,9 (RA). There was 
5% of acute skin toxicity grade ≥ 3 in the two cohorts and 35% 
of oesophageal toxicity grade≤ 2 in HT and 40% in RA. 
Conclusions: Rotational IMRT in complex adjuvant breast and 
nodes irradiation allows a good coverage of target volumes 
with an acceptable acute tolerance. A longer follow-up is 
needed to assess the impact of low doses to healthy 
tissues
 
Breast irradiation with HT in a patient with funnel chest 
(isodose 45 Gy) 
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Purpose/Objective: To investigate the feasibility and 
tolerance in the use of adjuvant Intensity Modulated 
Radiation Therapy (IMRT) and simultaneous integrated boost 
(SIB) in patients with a diagnosis of breast cancer after 
breast-conserving surgery (BCS). 
Materials and Methods: Between September 2011 to 
February 2013, 150 women with a diagnosis of breast cancer 
were treated with SIB-IMRT after BCS in our Institution. A 
dose prescription of 50 Gy in 25 fractions was prescribed to 
the whole breast (PTVbreast) and an additional dose of 
radiation on the tumour bed was prescribed (PTVboost). A 
dose prescription of 60 Gy in 25 fractions to PTVboost was 
used in patients with negative margins after surgery, whereas 
if the margins were close (< 1 mm) or positive (without a new 
surgical resection) a dose of 64 Gy was prescribed. All 
patients were followed with periodic clinical evaluation. 
